Description
B/T CLPD evaluation
CLPD Panel-CD5,CD23,CD19,CD3,CD22,CD20,CD10,FMC7,CD79b,CD38, CD103, CD25, Kappa, Lambda
B/T CLPD evaluation
TAT:
Specimen Type:
Flowcytometry Panel Test
Other Tests
- 260%
-
238%
CLPD panel-1 CD5,,CD23,CD19,CD3,CD10,CD79b,CD38,CD200, Kappa, Lambda
Kappa,Lamda,CD38,19,45,5,10,20,3,4,5,7,56,200,23,43,49d,FMC-7, Additiional CD103,123,25,11c
CLPD panel-1 CD5,,CD23,CD19,CD3,CD10,CD79b,CD38,CD200, Kappa, Lambda
Kappa,Lamda,CD38,19,45,5,10,20,3,4,5,7,56,200,23,43,49d,FMC-7, Additiional CD103,123,25,11c
-
90%
Acute Lymphoblastic Leukemia (ALL) Panel by PCR
E2A-PBX1; TEL-AML1; MLL-AF4; MLL-ENL; MLL-AF9; BCR-ABL1 (Major,Minor/Micro)
Acute Lymphoblastic Leukemia (ALL) Panel by PCR
E2A-PBX1; TEL-AML1; MLL-AF4; MLL-ENL; MLL-AF9; BCR-ABL1 (Major,Minor/Micro)
-
231%
CD 34
CD34+ cell quantification is necessary to determine the optimal timing and to confirm the adequacy of Peripheral Blood Stem Cell (PBSC) harvests. This assay also helps to determine when to perform Bone marrow stem cell transplants; whether to continue Apheresis and to assess bone marrow and Cord blood viability. CD34+ absolute count is a critical parameter for rapid and sustained engraftment.
CD 34
CD34+ cell quantification is necessary to determine the optimal timing and to confirm the adequacy of Peripheral Blood Stem Cell (PBSC) harvests. This assay also helps to determine when to perform Bone marrow stem cell transplants; whether to continue Apheresis and to assess bone marrow and Cord blood viability. CD34+ absolute count is a critical parameter for rapid and sustained engraftment.
Reviews
There are no reviews yet.